Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a rand...
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
About this item
Full title
Author / Creator
Motzer, Robert J, Dr , Hutson, Thomas E, DO , Glen, Hilary, MD , Michaelson, M Dror, MD , Molina, Ana, MD , Eisen, Timothy, Prof , Jassem, Jacek, Prof , Zolnierek, Jakub, MD , Maroto, Jose Pablo, MD , Mellado, Begoña, MD , Melichar, Bohuslav, Prof , Tomasek, Jiri, MD , Kremer, Alton, MD , Kim, Han-Joo, PhD , Wood, Karen, PhD , Dutcus, Corina, MD and Larkin, James, FRCP
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
SummaryBackgroundCurrently, metastatic renal cell carcinoma is treated with sequential single agents targeting VEGF or mTOR. Here, we aimed to assess lenvatinib, everolimus, or their combination as second-line treatment in patients with metastatic renal cell carcinoma. MethodsWe did a randomised, phase 2, open-label, multicentre trial at 37 centres...
Alternative Titles
Full title
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
Authors, Artists and Contributors
Author / Creator
Hutson, Thomas E, DO
Glen, Hilary, MD
Michaelson, M Dror, MD
Molina, Ana, MD
Eisen, Timothy, Prof
Jassem, Jacek, Prof
Zolnierek, Jakub, MD
Maroto, Jose Pablo, MD
Mellado, Begoña, MD
Melichar, Bohuslav, Prof
Tomasek, Jiri, MD
Kremer, Alton, MD
Kim, Han-Joo, PhD
Wood, Karen, PhD
Dutcus, Corina, MD
Larkin, James, FRCP
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1751228389
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1751228389
Other Identifiers
ISSN
1470-2045
E-ISSN
1474-5488
DOI
10.1016/S1470-2045(15)00290-9
